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ART ICLE Open Ac ce s s
Lrrc7 mutant mice model developmental
emotional dysregulation that can be alleviated by
mGluR5 allosteric modulation
Chi Ho Chong1, Qi Li2, Priscilla Hoi Shan Mak1, Cypress Chun Pong Ng1, Eva Hin Wa Leung1, Vicky Huiqi Tan1,
Anthony Kin Wang Chan1, Grainne McAlonan3 and Siu Yuen Chan 1
Abstract
LRRC7 has been identified as a candidate gene for severe childhood emotional dysregulation. Direct experimental
evidence for a role of LRRC7 in the disease is needed, as is a better understanding of its impact on neuronal structure
and signaling, and hence potential treatment targets. Here, we generated and analyzed an Lrrc7 mutant mouse line.
Consistent with a critical role of LRRC7 in emotional regulation, mutant mice had inappropriate juvenile aggressive
behavior and significant anxiety-like behavior and social dysfunction in adulthood. The pivotal role of
mGluR5 signaling was demonstrated by rescue of behavioral defects with augmentation of mGluR5 receptor activity
by 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB). Intra-peritoneal injection of CDPPB alleviated
abnormal juvenile behavior, as well as anxiety-like behavior and hypersociability at adulthood. Furthermore, mutant
primary neurons had impaired neurite outgrowth which was rescued by CDPPB treatment. In conclusion, Lrrc7 mutant
mice provide a valuable tool to model childhood emotional dysregulation and persistent mental health comorbidities.
Moreover, our data highlight an important role of LRRC7 in mGluR5 signaling, which is a potential new treatment
target for anxiety and social dysfunction.
Introduction
Densin-180, also named Leucine-rich repeat containing
protein 7 (LRRC7), is an abundant scaffold protein ori-
ginally isolated from the postsynaptic density1. LRRC7 is
located at 1p31.1, a region linked to neurodevelopmental
conditions including severe language impairment2 and
autism spectrum disorder3. Importantly, LRRC7 has
recently been identified as a candidate gene for serious
childhood emotional dysregulation. Specifically, in a
genome-wide association study of the Child Behavior
Checklist in children and adolescents with attention
deficit-hyperactivity disorder (ADHD), SNPs in LRRC7
were linked to the highest scores on the CBCL–DP (Child
Behavior Checklist–Dysregulation Profile)4. High scores
on CBCL–DP place an individual at an increased risk of
developing serious mood disorder, anxiety, personality
difficulties, and aggressive behavior which persist into
adulthood5–7. Therefore, it is essential to understand the
function of LRRC7 in brain to elucidate the molecular
mechanism of the above neurodevelopmental disorders.
LRRC7 interacts with proteins such as CaV1.2 channel,
NMDA (N-methyl-D-aspartate) receptors, CaMKIIα
(Ca2+/calmodulin-dependent protein kinase II α), δ-cate-
nin, α-actinin, SHANK, and Maguin-1 (refs. 8–14). These
targets have themselves been linked to a broad spectrum
of neurodevelopmental disorders including autism and
intellectual disability15–22. mGluR5 dysfunction is also
associated with neurodevelopmental disorders including
autism spectrum disorder and attention deficit hyper-
activity disorder23–27. Emotional dysregulation is a
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common characteristic across such neurodevelopmental
psychiatric disorders28,29. With increasing numbers of
patients diagnosed with these lifelong conditions30–32, a
better understanding of the underlying molecular
mechanisms is crucial to developing effective
interventions.
Although no experimental evidence suggests molecular
interaction between LRRC7 and mGluR5, there have been
some valuable first steps. Deletion of Lrrc7 in C57BL/6
mice by gene targeting has been reported to reduce the
level of postsynaptic mGluR5, and impaired mGluR-
induced long term depression. By contrast, recruitment
and function of NMDA receptors are normal at synap-
ses33. However, to date, there is no direct evidence to link
mGluR5 abnormalities to behavioral abnormalities in
animals with Lrrc7 deletion.
It has been well-established that mGluR5 regulates
synaptic strength34–36, and indirect evidence shows that
mGluR5 also plays a role in early neurite development. In
the zebrafish model of Fragile X syndrome, pharmacolo-
gical mGluR5 inhibition corrects neurite branching
defects37; whereas in mice, deletion of mGluR5 in layer 2/
3 pyramidal neurons of somatosensory cortex impairs
dendritic arborization38. The link between mGluR5 and
scaffold proteins in neurite morphogenesis and the
underlying signaling remains unexplored.
Therefore, we analyzed Lrrc7 hypomorphic mutant
mice which we had fortuitously generated. We aimed to
confirm a behavioral phenotype relevant to develop-
mental emotional dysregulation. We then tested whether
impaired mGluR5 signaling plays a pivotal role in causing
these defects by attempting behavioral rescue through a
positive allosteric modulator (PAM) of mGluR5. We tes-
ted the hypothesis that LRRC7 also enhances mGluR5-
mediated neurite growth using primary embryonic neu-
rons. Finally, we tested the prediction that augmenting
mGluR5 signaling would rescue the neurite growth
defects of LRRC7-deficient neurons.
Materials and methods
Mice
Experiments were approved by the Committee on the
Use of Live Animals in Teaching and Research at the
University of Hong Kong. The Lrrc7 mutant mouse line
was generated through insertional mutagenesis via
microinjection of DNA into fertilized FVB/N mouse
oocytes. Southern blot and inverse PCR showed inser-
tion of a single copy of the transgene into intron 1 of
Lrrc7 gene (Supplementary Fig. S1A, B). Expression of
Lrrc7 was impaired (Fig. S1C). Western blot with
antibodies for LRRC7 (Santa Cruz, cat. sc-28947)
detected a trace amount of protein in homozygotes
(Fig. S1D). RT-qPCR using two pairs of primers both
indicated that homozygotes expressed 2% of wild-type
transcripts (Fig. S1E). Primer sequences are available
upon request.
We inter-crossed heterozygous mice to maintain the
line. Lrrc7 homozygous mutants appeared smaller in size
since the second week of age and needed to be fed with
wet chow from postnatal day (P)17 to P32, otherwise they
died of dehydration. Injuries were found in littermates
and recorded. A paper house was provided from birth to
reduce fighting which otherwise could be fatal. Mice were
weaned at around P21 but small mice were allowed to be
kept with their mother until P28–P32. The weight of lit-
termates was monitored starting from P14 to 36. At P16,
the hanging wire test was used to assess motor strength
before the genotype was known. The mouse was placed
on the top of the cage lid. After the mouse gripped onto
the wire, the lid was turned upside down. The time taken
for the mouse to fall off was measured with the cut-off
time set at 1 min.
Behavioral tests
The estimation of sample size was based on the data
from exploratory studies of behavior. According to PASS
software (NCSS Statistical Software), eight mice should be
assigned to each group to allow randomized block analysis
of variance power analysis with alpha= 0.05 and power=
0.80. Mice used in behavioral experiments were litter-
mates collected from heterozygous pairings. Mice born
within the same week were employed as a cohort. Mice
were tested from 8 weeks of age and tests were performed
during the light cycle. The test was performed and ana-
lyzed with the genotype blinded.
The hanging wire test was used to re-assess motor
strength. The time taken for the mouse to fall off from
the inverted cage lid was measured. To assess behavior
related to emotional dysregulation, the open field and
elevated-plus maze paradigms were used to measure
“anxiety”; the one-chamber and three-chamber tests
were used to measure social interaction. Sucrose pre-
ference and forced swim tests were used to assess
”depression”; the Y-maze was used to examine working
memory. Except for the hanging wire test and open field
test, only males were employed. For the open field test,
males and females behaved similarly and therefore their
data were pooled.
The open field consisted of a square arena of dimension
40 × 40 × 40 cm with a marked center zone of 13.5 ×
13.5 cm. The subject mouse was allowed to freely explore
in the box for 10min. Videos taken from an overhead
camera were analyzed automatically using Ethovision
XT7.1 (Noldus Information Technology). The data of
time spent and entry to the center zone were extracted.
The elevated-plus maze consisted of two opposite close
arms and two opposite open arms and was elevated at a
height of one meter. The subject mouse was gently placed
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in the center facing the close arm, and allowed to explore
the maze freely for 10min with video recording. Videos
were analyzed with Ethovision XT7.1.
Wild-type males were used as strangers. In the one-
chamber test, the subject mouse and a stranger mouse
were introduced into a square arena of 25 × 25 × 25 cm
and allowed to interact freely for 6 min. Time spent on
following and sniffing the stranger mouse was scored
manually from video recordings by a trained rater. The
three-chamber apparatus consists of a Plexiglas box of
60 cm (L) × 40 cm (W) × 22 cm (H), divided into three
chambers by transparent walls with an entry door to the
middle chamber. The subject mouse was placed in the
center chamber and allowed to habituate for 10min with
the doors open. Following that, it was gently moved to the
center chamber and doors were closed. In one side of the
chamber an unfamiliar mouse (stranger 1) was held
within a wired cage, while an empty wired cage was placed
in the chamber at the opposite end. The subject mouse
was allowed to explore all three chambers for 10min.
Then, another unfamiliar mouse (stranger 2) was added to
the wired cage in the opposite chamber. The test mouse
was allowed to explore for another 10min. Movements
were video-taped and social interaction was scored
manually by a trained rater.
In sucrose preference test, the subject mouse was singly
caged and deprived of water the day before the test. To
start (day 1), a bottle of water and a bottle of 2 % sucrose
solution were provided. Both bottles were weighed every
24 h and their positions were switched to avoid position
bias. Sucrose preference was measured by
Volume of sucrose consumed
Total volume consumed ´ 100% for six consecutive days. In
forced swim test, a beaker of 18 cm in height and 13 cm in
diameter was filled with 2 L of water and the subject
mouse was gently placed inside. Their swimming time and
immobile time were recorded for 6 min.
For the Y-maze test, the subject mouse was placed in a
Y-shaped maze with three opaque arms at 120 ° from each
other. The subject mouse was allowed to freely explore
the maze for 10min. The number of three consecutive
alternations (ABC, ACB, BCA, BAC, CAB, CBA) was
counted. Percentage alternation was calculated as
Number of 3 consecutive alternations
Total number of arm entries ´ 100%.
Semi-quantitation of synaptic proteins
Cortices were dissected out and synaptosomal-enriched
(P2) fraction was prepared as described39. Ten micro-
grams protein samples were loaded for western blot
analysis. Proteins were detected with antibodies for
mGluR5 (Abcam, cat. AB76316) and β-tubulin (Sigma,
cat. T8328). Signal intensities were quantitated with
ImageJ and normalized with the band intensity of
β-tubulin.
Behavioral rescue
With reference to the dosages used in other studies24,40,
CDPPB (Tocris) was dissolved in DMSO to a concentra-
tion of 10 mg/ml, and mixed with PBS containing 10%
Tween-80 in a 1:9 ratio for intraperitoneal injection. PBS
containing 10% Tween-80 was given as vehicle. Mice were
given a single intraperitoneal injection at 10 mg/kg/day
from P16 to 22. The whole little was weaned at P35.
For rescue experiments performed in adult mice, only
males were employed. CDPPB (10 mg/kg) was injected
30min before the open field test and three-chamber test.
Cortices were collected within 10min after the open field
test. Protein samples were prepared in IP buffer supple-
mented with inhibitors including sodium orthovanadate.
Samples were probed with antibodies against phospho-
ERK (Cell Signaling, cat. 9101), total ERK (Cell Signaling,
cat. 9102), phospho-JNK (Cell Signaling, cat. 9251), and
total JNK (Cell Signaling, cat. 9252).
Dendrite morphology in adult hippocampus
Brains were collected from adult male littermates.
Golgi-Cox staining procedures were performed following
the manufacturer’s instructions (FD Neurotechnologies).
Brains were sectioned coronally at 150 µm and hippo-
campal CA1 pyramidal neurons were reconstructed and
analyzed blinded using Neurolucida software (MBF
Bioscience). For comparing spine density and length, only
spines in the secondary branches of apical dendrites were
measured.
Primary neuronal culture
Littermatte embryos derived from heterozygous parents
were collected at day 16.5 of gestation. The hippocampus
was dissected and dissociated in 0.0125% trypsin. Dis-
sociated cells were plated at a density of 10,000 cells/cm2
on poly-D-lysine-coated coverslips in a 24-well plate, and
cultured with neurobasal medium containing 1% B27,
2 mM GlutaMax, 25 µM L-glutamate and 1% penicillin/
streptomycin for 24 h [0 day in vitro (DIV)]. Half of the
medium was replaced with medium without L-glutamate
on the next day.
Neurons were transfected with pEGFP (Clontech) on 5
DIV using calcium phosphate precipitation. Photo-
micrographs were taken on 7 DIV and analyzed blinded to
genotype with the Imaris imaging software (Bitplane).
The mGluR5 antagonist 2-methyl-6-(phenylethynyl)
pyridine (MPEP) (Abcam) was dissolved in PBS at 5 mM
and added to culture on 3 DIV at a final concentration of
10 µM. Hippocampal neurons were transfected with
pEGFP and neurite analysis was performed as described
above. In rescue experiment, CDPPB (Tocris) was dis-
solved in DMSO (27.4 µM) and added to culture to reach
a final concentration of 50 nM on 3 DIV.
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Statistical analysis
Behavioral data were collected from at least two dif-
ferent cohorts of mice except for one chamber test and
juvenile drug rescue. Golgi analysis data were collected
from three individual animals of each genotype. Mor-
phometric analysis of primary neurons was performed on
three independent experiments. Two-tailed unpaired
Student t-test, one-way ANOVA with Tukey’s post hoc
test, Bartlett’s test for equal variance, and two-way
ANOVA with Bonferroni post hoc test were conducted
using GraphPad Prism software. Pairwise comparisons of
growth curves in vehicle and CDPPB-treated mice were
made using SPSS. All data are represented as mean ±
SEM .
Results
Increased anxiety and abnormal social interaction in Lrrc7
deficient mice
Mutants began to show abnormal behavior at the third
to fourth week of age, regarded as the juvenile stage.
Homozygotes followed their littermates excessively and
this resulted in “fighting” and injuries. There was a direct
correlation between the percentage of injured mice and
the percentage of homozygotes in litter (Fig. 1a). Besides,
homozygotes were smaller in size around weaning, but
they “caught-up” at the fifth week (Fig. 1b). We checked
whether mutant mice at P16 were of reduced motor
strength which could affect their feeding and drinking. All
tested mice were able to grip firmly and hanged for at
least 11 s, but more mutant mice dropped off before the
one minute cut-off time (one-way ANOVA P= 0.0126,
Tukey’s post hoc test P= 0.0176 between wild-type and
homozygotes; Fig. 1c).
Standard behavioral tests reported below were per-
formed in young adults of 8–10 weeks old. Mutant mice
had normal motor strength as measured by the hanging
wire test at 8 weeks of age (mutant: 38.1 ± 5.5 s, n= 8 vs
wild-type: 34.2 ± 5.4 s, n= 9). In the open field test,
mutant mice had normal locomotion as measured by the
total distance traveled. However, homozygous mutants
showed markedly elevated anxiety as reflected by the
significantly fewer entries to the center zone and less time
spent inside the center zone (Fig. 1d). The elevated-plus
maze confirmed significant “anxiety” in the homozygotes
(Fig. 1e).
To evaluate social behavior of mice, one-chamber and
three-chamber tests were used. No aggressive behavior of
the mutant was observed in the one-chamber test.
Homozygotes spent significantly more time in sniffing
both in the one-chamber test (Fig. 1f) and in the three-
chamber test (Fig. 1g). Compared to the wild-type, het-
erozygotes also spent significantly more time sniffing the
stranger mouse (Fig. 1g). Thus, social interaction was
disrupted by LRRC7 deficiency.
To evaluate depressive behavior, sucrose preference
test was used to measure anhedonia, a core symptom in
depression. Mutant mice showed a mild defect in sucrose
consumption only on the first day of habituation but not
the remaining 5 days (Fig. 1h), suggesting no anhedonia.
In the forced swim test, mutant mice did not give up
swimming throughout 6 min of the test, while the
wild-type had 23 ± 9.58 s of immobility time (Student’s
t-test, P < 0.0001, n= 6 each). Therefore, there was no
evidence of depression. In the Y-maze test of spatial
working memory, mutant mice showed less alternation in
arm entries (Fig. 1i).
In summary, the mutant mice showed anxiety-like
behavior, abnormal social behavior, signs of working
memory defects but not depression-like features.
Amelioration of behavioral defects by potentiating
mGluR5 receptor signaling
Since we detected a near significant reduction in the
expression of mGluR5 in synaptosome-enriched fraction
of brain lysates of mutants collected at P28 (Fig. S2), we
moved on to test the beneficial effect of augmenting
mGluR5 signaling by using a PAM that can cross the
blood brain barrier41. We confirmed that at P16, there
was a reduction in the synaptosomal level of mGluR5 in
some of the mutants but overall there was no significant
difference between genotypes (Fig. 2a). As homozygous
mutant mice were profoundly smaller than littermates at
days 24 to 28, we tested whether daily injection of
CDPPB from P16 to 22 could be preventive (Fig. 2b).
The result showed that mutant mice were still below
normal weight at P28 to P30, but they had significantly
better weight gain compared to vehicle injected mutants
(Fig. 2c). Furthermore, fighting and injuries were less
apparent on P26 (Fig. 2d). This effect did not persist and
more injured mice were observed 2 days later and
mutant mice showed anxiety-like behavior in the open
field test at 8 weeks (Fig. S3).
To further explore the therapeutic potential of CDPPB,
we tested if acute injection of the drug in treatment naive
mice could ameliorate anxiety-like behavior and hyper-
sociability. Injection of CDPPB 30 min before the open
field test or three-chamber test eliminated the difference
between wild-type and homozygous mutants in terms of
the number of center entries and the duration in the
center (Fig. 3a); CDPPB also restored the sniffing time of
the mutants to normal in the three-chamber test when
only stranger 1 was present (Fig. 3b, left). When stranger
2 was introduced, there was also significant reduction in
sniffing time both toward strangers 1 and 2 (Fig. 3b,
right).
Brain lysates were collected from cortices right after
open field test for investigating the effect of CDPPB
injection on known mGluR5 downstream signaling
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Fig. 1 (See legend on next page.)
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pathways42. Without CDPPB treatment, we detected
impaired phosphorylation of ERK, but not JNK, in
mutant cortices. Mice treated with CDPPB 30 min before
the test did not show this difference (Fig. 3c).
Lrrc7 is important in dendrite morphogenesis
The in vivo significance of LRRC7 in dendritic branching
is not well established. Therefore, we analyzed the mor-
phology of Golgi-stained pyramidal neurons from the CA1
(see figure on previous page)
Fig. 1 Behavioral problems relevant to emotional dysregulation in Lrrc7 mutant mice. a Juvenile mutant mice caused injury to littermates as
illustrated by a positive correlation between the percentage of injured mice and the percentage of homozygous mutants within the litter counted at
day 26 of age. n= 17 litters, 8–10 mice per litter (Pearson correlation, P < 0.0001). b Transient growth retardation of homozygotes around weaning
(two-way repeated measure ANOVA, genotype: F(2,374)= 84.43, P= 0.00014; Bonferroni post hoc test, *P < 0.05, ***P < 0.001). c Wire hanging time of
day 16 mice (one-way ANOVA P= 0.0126; Tukey’s post hoc test, *P < 0.05). Data collected from six litters. d–i Behavioral tests at young adulthood:
d Mutants showed anxiety behavior in the open field test (center entries: one-way ANOVA, P < 0.0001; center duration: one-way ANOVA, P < 0.0001.
Tukey’s post hoc test, ***P < 0.001, ****P < 0.0001). e Anxiety behavior in the elevated-plus maze as indicated by increased time spent in close arms
and reduced entries to open arms (two-way ANOVA, time spent in arms: genotype: F(1,38)= 46.69, P < 0.0001; arm entries, genotype: F(1,38)= 13.06,
P= 0.0009; Bonferroni post hoc test, ***P < 0.001). f Heterozygous and homozygous mice showed a trend of increased social interaction with the
stranger mouse (Sniffing: one-way ANOVA, P= 0.0399, Tukey’s post hoc test, *P < 0.05; following: one-way ANOVA, P= 0.0623). g Increased sociability
of heterozygous and homozygous mutants in the three-chamber test (two-way ANOVA: Sociability, genotype: F(2,40)= 34.90, P < 0.0001; Social
Novelty, genotype: F(2,40)= 13.75, P < 0.0001; Bonferroni post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001). h Mutant mice showed a significantly
reduced preference for sucrose solution on the first day of test (two-way repeated measure ANOVA, genotype: F(1,185)= 6.99, *P= 0.011; Bonferroni
post hoc test, **P < 0.01). i Impaired spatial working memory as suggested by reduced alternation in arm entry in Y-maze (one-way ANOVA, P=
0.003; Tukey’s post hoc test, *P < 0.05, ***P < 0.001). Number of mice indicated in graph or under n in diagram. +/+ wild-type; +/m heterozygotes;
m/m: homozygous Lrrc7 mutant
Fig. 2 Daily intraperitoneal injection of CDPPB in juvenile mutant mice has transient beneficial effects. a A trend of reduced synaptic mGluR5
in mutants (one-way ANOVA, P= 0.1707, n indicated in graph). b Schematic diagram of the CDPPB treatment protocol. The whole litter of mice from
heterozygous breeding pairs was kept with their mother throughout the experiment. c Homozygous mutant mice had significantly better weight
gain after drug treatment (two-way repeated measure ANOVA, group: F(3,490)= 6.59, P= 0.0012; no significant difference between +/+ and +/m. P
< 0.001 for all other pairwise comparison between two groups. Number of mice (n) indicated in graph. Data collected from seven litters. d Same mice
showed a trend of reduced injury when counted at postnatal day 26 in CDPPB-treated litters (P= 0.236). +/+, wild-type; +/m, heterozygotes; m/m,
homozygous Lrrc7 mutant
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Fig. 3 Acute injection of CDPPB alleviates the anxiety-like behavior and excessive social interaction in mutant mice. a Injection of CDPPB
30min prior to the test restored normal behavior of mutant mice in the open field. Moving tracks of mice and parameters in 10 min were shown
(two-way ANOVA: total distance, drug: F(1,33)= 4.24, P= 0.0475; center entries, genotype: F(1,33)= 4.99, P= 0.0324; center duration, genotype: F(1,33)=
4.19, P= 0.0487). b CDPPB alleviated hypersociability in mutant mice in the three-chamber test (two-way ANOVA: Sociability—stranger 1, genotype:
F(1,37)= 16.50, P= 0.0002, drug: F(1,37)= 9.37, P= 0.0041; Social novelty—stranger 1, genotype: F(1,37)= 20.02, P < 0.0001, drug: F(1,37)= 8.05, P <
0.0074; Social novelty—stranger 2, genotype: F(1,37)= 19.38, P < 0.0001, drug: F(1,37)= 3.61, P= 0.0651) (a, b, Bonferroni post hoc test *P < 0.05, **P <
0.01, ***P < 0.001; n.s., not significant. Number of mice indicated in graph on the left). c Normal JNK but impaired ERK1 signaling (arrow) in the
mutant cortex. Protein lysates were collected within 10 min after the open field test. Quantitation of western blot shown on the right. *P < 0.05, **P <
0.01, Student t-test; +/+, wild-type; m/m, homozygous Lrrc7 mutant
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region of adult hippocampus and compared between lit-
termates. Mutant neurons had significantly elongated spine
neck (Fig. 4a). Moreover, Sholl analysis of the 3D recon-
structed CA1 neurons revealed that mutant neurons were
less complex than wild-type (Fig. 4b). Specifically, mutants
had significantly reduced length and branching starting at
the third order for basal dendrites. For the apical dendrites,
this occurred at the fifth order of branching and became
significant at the seventh and eighth order (Fig. 4c).
LRRC7 regulates neurite morphogenesis via
mGluR5 signaling
As we found that neurite morphogenesis was sig-
nificantly impaired in mutants, we used primary neuronal
Fig. 4 Deficiency in LRRC7 causes reduced dendritic arborization in the hippocampus. a Mutant pyramidal neurons in the hippocampus
showed elongated dendritic spines (arrows). Secondary apical dendrites of neurons from the CA1 region were analyzed by Neurolucida software.
Student's t-test, **P < 0.01. No. of dendrites analyzed indicated in graph; three mice per genotype. b Reduced dendritic complexity in mutant
hippocampal neurons as shown by Sholl analysis (Genotype, two-way ANOVA: F(1, 864)= 309.5, ***P < 0.0001). c Reduced length and branching in
both basal and apical dendrites in mutant pyramidal neurons as analyzed by Neurolucida software (Basal: total length, Student's t-test, ***P < 0.001;
length per order, two-way ANOVA: genotype: F(1, 112)= 50.42, P < 0.0001; number of branch per order, genotype: F(1, 112)= 94.77, P < 0.0001; apical:
total length, Student's t-test, ***P < 0.001; length per order, two-way ANOVA: genotype: F(1, 240)= 17, P < 0.0001; number of branch per order,
genotype: F(1,240)= 33.21, P < 0.0001). Bonferroni post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001. Number of neurons in b and c: +/+, wild-type=
14; m/m, mutant= 15 from three mice each
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cultures to test whether LRRC7-mGluR5 directly controls
this process. Primary hippocampal neurons were trans-
fected with EGFP plasmid at 5 DIV for accurate tracing
of neurites at 7 DIV. Similar to ex vivo tissues from adult
animals, neuron morphogenesis was impaired in
mutants (Fig. 5a). To validate that mGluR5 signaling is
important for neurite development, we treated neurons
with the selective mGluR5 antagonist MPEP. The
treatment reduced the total number of branch points
and the total neurite length in wild-type neurons, but did
not further reduce neurite growth in mutant neurons
(Fig. 5b). Finally, we tested whether neurite growth could
respond to CDPPB treatment. We applied CDPPB to the
cultures since 3 DIV, transfected with EGFP at 5 DIV
and measured neurite growth 2 days later. With CDPPB,
both the number of branch points and neurite length
were restored in the mutant (Fig. 5c).
Discussion
The importance of scaffold proteins in synapse develop-
ment and hence neurodevelopmental conditions such as
ADHD, autism spectrum disorder, bipolar disorder, and
schizophrenia is increasingly recognized20,24,43–45. Here we
report that disruption of the Lrrc7 gene, which has been
linked to serious childhood emotional dysregulation4,
impairs signaling of mGluR5. The functional consequences
comprise anxiety and social interaction impairments ana-
logous to the difficulties reported in individuals with neu-
rodevelopmental conditions. In addition, we provide the
first evidence that both behavioral and cellular phenotypes
of these mutant animals can be rescued by CDPPB, con-
firming a crucial role for mGluR5 signaling in this model of
emotional dysregulation. Using primary hippocampal neu-
rons to examine neurite growth, we also established a new
role of LRRC7–mGluR5 signaling in neurite aborization.
Fig. 5 LRRC7 enhances mGluR5 signaling in neurite growth. a EGFP transfected hippocampal neurons were measured at 7 DIV. Mutant neurons
showed reduced neurite growth. Student's t-test, ***P < 0.001. b mGluR5 specific antagonist MPEP reduced branch number and length in wild-type
neurons, but did not further reduce neurite growth in mutant neurons (two-way ANOVA: branch points, drug: F(1,63)= 7.99, P= 0.0063; length, drug:
F(1,63)= 8.72, P= 0.0044, Bonferroni post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001). c Addition of CDPPB rescued the neurite growth defect in
mutant neurons (two-way ANOVA: branch points, genotype: F(1,42)= 5.55, P= 0.0232; length, genotype: F(1,42)= 5.68, P= 0.0218). Bonferroni post hoc
test, *P < 0.05, **P < 0.01, n.s., not significant. Number of neurons as indicated in bars. Neurons collected from three independent experiments. +/+,
wild-type; m/m, homozygous Lrrc7 mutant
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In mice, an Lrrc7 loss-of-function mutant line on the
C57BL/6 genetic background has been reported to be
small at weaning and to develop anxiety, excessive fight-
ing, impaired short-term memory, and disrupted sensor-
imotor gating33. Here, we found that our mutant mice
were also small around the time of weaning, and had
anxiety-like behavior. However, in our studies, the rearing
conditions also affected the phenotypic manifestation. We
provided a paper house in the cage since this practice
reduced fighting and fatal attacks. We also analyzed the
social interaction of the mutant mice with strangers and
found hypersociability in mutant mice, with heterozygotes
showing a milder phenotype than homozygotes. For
anxiety-like behavior, even though the heterozygous mice
behaved normally in the open field test, we found in the
behavioral rescue experiment that stress at the juvenile
stage could lead to anxiety-like behavior in adulthood
(Supplementary Fig. S3). Taken together, reduced
expression of Lrrc7 had a profound impact on anxiety and
social behavior on different genetic backgrounds, with
manifestation influenced by rearing conditions.
It is important to test whether early drug intervention
could be beneficial or even preventive in developmental
disorders. In particular, adolescent administration of
mGluR5 PAMs can prevent adult-onset deficits induced
by neonatal treatment with phencyclidine40; and 1 week
administration with a mGluR5 PAM attenuated sensor-
imotor gating deficits in a similar model46. When CDPPB
was given for 7 days at juvenile stage in our mouse model,
it was effective in improving weight gain and reducing
juvenile fighting. Furthermore, a single injection of
CDPPB in adult mutants significantly alleviated the
anxiety-like behavior in the open field test and hyper-
sociability in the three-chamber test. Thus, although
LRRC7 controls neuron morphogenesis since early
development, the effects of its loss are not completely
irreversible in the mature brain. This is very promising
and fits with other preclinical studies that mGluR5 may be
a tractable drug target. For example, acute CDPPB
injection is effective in alleviating abnormal behaviors in
rodent models of schizophrenia41, tuberose sclerosis24,
and autism spectrum disorder47. Augmentation of sig-
naling by PAMs instead of mGluR agonists has the
potential advantage of high receptor subtype selectivity
and low receptor desensitization48–50; PAMs also main-
tain the intrinsic regulatory systems for neurotransmitter
release48–50. Furthermore, improved mGluR5 PAMs have
been developed including one which is effective when
given orally51.
New treatment targets for socio-emotional disorders
across the life-span are much needed. In clinical settings,
treatments targeting mGluR5 are starting to be investi-
gated. These include AFQ056, an mGluR5 antagonist,
which is being trialed in people with obsessive compulsive
disorder who are resistant to selective serotonin reuptake
inhibitors (Trial no. NCT01813019). Especially in chil-
dren, the need for safer and more effective interventions
for serious mood and emotion difficulties is most marked
because medications such as selective serotonin reuptake
inhibitors, commonly used in adults52, are not ideal for
children53. In adolescents with ADHD and glutamatergic
gene network variants, fasoracetam, which activates
mGluRs, has completed Phase 1 trial54. We suggest
LRRC7 genotyping could be incorporated in future patient
stratification. This group of patients will potentially ben-
efit from mGluR5 PAMs or drugs such as fasoracetam.
The detailed mechanism of how LRRC7 affects
mGluR5 signaling and how CDPPB alleviates the beha-
vioral defects remain to be established. In the synapse, one
proposed mechanism is LRRC7 indirectly affects the
localization of mGluR5 through reducing the amount of
α-actinin, a common interacting protein of mGluR5 and
LRRC7 (ref. 33). For repeated treatment, there are also
indirect effects of mGluR5 PAMs on the expression of
NMDA receptors in specific brain regions in rat models55.
In conclusion, Lrrc7 mutant mice may provide a valu-
able tool to model developmental emotional dysregulation
and persistent mental health difficulties. The model
has allowed us to pinpoint the importance of
LRRC7–mGluR5 pathway in behavioral control. Our data
highlight the acute effect of mGluR5 PAM in treatment of
anxiety and socio-emotional disorders. Issues such as
treatment duration and dosage responses, as well as the
long-term outcome have to be resolved. Furthermore,
both female and male mutant mice were affected but we
used males only in the social interaction tests and the
rescue experiments. Given the possibility of different
pharmacological responses to drugs in males and
females56, a comprehensive study in both sexes is war-
ranted. Detailed mechanistic study on how the mature but
elongated spines restructure and function, and how they
response to drug treatment will provide further insights
into the role of scaffold protein in signaling and synaptic
plasticity. We hope this work will encourage further
translational studies in the clinical setting.
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